HOCHDORF Holding AG
HOCHDORF Holding Ltd: Information for the extraordinary Meeting of Shareholders
EQS Group-Ad-hoc: HOCHDORF Holding AG / Key word(s): AGM/EGM HOCHDORF Group Press Release: Extraordinary Meeting of Shareholders Details of the request for conditional capital increase Hochdorf, 4 November 2016 – At the Extraordinary General Meeting of HOCHDORF Holding Ltd on 29 November 2016, the shareholders will decide upon a conditional capital increase, an increase in the voting restriction of 5% to 15% and the election of Michiel de Ruiter to the Board of Directors at HOCHDORF Holding Ltd. Details of the implementation of the conditional capital increase are now available. On 24 October 2016 HOCHDORF signed the purchase agreement to acquire 51% of Pharmalys Laboratories SA, Baar (Switzerland), 51% of Pharmalys Tunisia SA, Tunis (Tunisia) and 51% of Pharmalys Africa Sarl, which will be jointly founded as a new company. Details of the implementation of the conditional capital increase in relation to this transaction are now available. The capital increase will be presented to the shareholders for approval. Details of the purchase price Mandatory convertible bond in two tranches At the Extraordinary General Meeting, the Board of Directors is requesting a conditional share capital increase to a maximum amount of CHF 7,173,800 by issuing a total of 717,380 fully paid-in registered shares with a nominal value of CHF 10.00 per share, in order to issue a mandatory convertible bond. The planned mandatory convertible bond will be paid up on 31.3.2017. The runtime of the bond is 3 years. The interest coupon is set at 3.50% and the strike price is CHF 304.67. This corresponds to the volume-weighted average share price of 25 October 2016 with an additional premium of CHF 30. The maximum issue amount is therefore around CHF 218.5 million. Of this overall amount, a maximum of CHF 131.0 million is reserved as tranche A for the purchase of the Pharmalys companies. The advance subscription rights of previous shareholders are suspended for tranche A in favour of the seller. The remaining tranche B of at least CHF 87.5 million will be offered to the previous shareholders in full as advance subscriptions. The invitation to the Extraordinary General Meeting as well as answers to questions relating to the Pharmalys transaction are available on the HOCHDORF Group website: www.hochdorf.com. Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=IUOOJQRWRF Document title: Information for the Extraordinary Meeting of Shareholders End of ad hoc announcement Information and Explanation of the Issuer to this News: In 2015 the HOCHDORF Group, which is headquartered in Hochdorf, generated a consolidated gross sales revenue of CHF 551.2 million. It is one of the leading foodstuff companies in Switzerland, with more than 625 employees as at 31 December 2015. Made from such natural ingredients as milk, wheat germ, and oilseeds, HOCHDORF products have been contributing to the health and well-being of the young and old alike since 1895. Our customers include the food industry and wholesalers and retailers. Our products are sold in more than 90 countries. HOCHDORF stock is traded on the SIX Swiss Exchange in Zurich (ISIN CH0024666528). |
Language: | English | |
Company: | HOCHDORF Holding AG | |
Siedereistrasse 9 | ||
6281 Hochdorf | ||
Switzerland | ||
Phone: | +41 41 914 65 65 | |
Fax: | +41 41 914 66 66 | |
E-mail: | hochdorf@hochdorf.com | |
Internet: | www.hochdorf.com | |
ISIN: | CH0024666528 | |
Listed: | SIX Swiss Exchange | |
End of News | EQS Group News Service |